Twenty year survival of advanced gastrointestinal stromal tumours treated with imatinib Exploratory long-term follow-up of the BFR14 trial
{{output}}
Background: Gastrointestinal stromal tumors (GIST) are driven in >75% of patients by mutations in KIT and PDGFRA kinases. Imatinib, a tyrosine kinase inhibitor, has shown efficacy in metastatic GIST but the long-term survival imp... ...
